View footage from the Global Interdependence Center’s Central Banking Series in Dublin, September 2016
Irish early stage investment company Lucey Fund is looking for startups!
The Lucey Fund is leading the wave of very early stage Tech Angel investing and have invested in 80+ startups in the past 3 years, 30 of which were in the past 12 months, with plans to make 50+ in 2016. They are seeking new investment opportunities at Venturef0rth, come meet the Founder Ian Lucey and tell them more about your startup!
To register, please click HERE.
ICON Announces Senior Appointments in Scientific Operations, Medical Imaging and Real World Evidence
Dublin, Ireland, 12th October 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced senior appointments to its clinical research, medical imaging and commercialisation and outcomes services. Dr. Andrew Garrett has been appointed Executive Vice President, Scientific Operations, Dr. Paul McCracken has joined ICON as Vice President, Medical Imaging and Mr. Jim Carroll has been appointed Vice President, Real World Evidence (RWE).
Oct10Mon
|
Almac Group Discover an Exciting Link between its Immune Response Assay and Checkpoint Inhibitor Based Therapy Study Published in JNCI |
|
 Craigavon, N.I., 10 October 2016 – Almac Group’s Diagnostics business unit today announced the identification of a novel immune response mechanism in breast tumours deficient in DNA repair. The study has been published in the Journal of the National Cancer Institute (JNCI).The publication entitled ‘Activation of STING-Dependent Innate Immune Signalling By S-Phase-Specific DNA Damage in Breast Cancer’ follows on from Almac’s previous publication of a 44 gene immune based assay capable of prospectively identifying breast cancer patients with a defect in the FA/BRCA pathway who benefit from anthracycline based chemotherapy.
|
Oct04Tue
|
Almac Diagnostics Partner with ArcherDX |
|
| Craigavon, N.I., UK & Boulder, CO – 04 October 2016 – Almac Group’s Diagnostics business unit today announced its partnership with ArcherDx to provide FusionPlex® and VariantPlex NGS assays as part of their CDx partnership solutions.ArcherDX, the leader in NGS-based fusion detection assays and software, has also approved Almac Diagnostics as a Certified Service Provider (CSP) of Archer® NGS assays. This agreement further establishes Almac Diagnostics as a trusted partner providing scientific and technological excellence globally.Almac Diagnostics, the personalised medicine business unit of the Almac Group partners with Biopharma on the discovery, development and commercialisation of diagnostic tests including companion diagnostics. It also has an internal portfolio of both prognostic and predictive assays in development across a wide range of disease areas. Read More |
Sep22Thu
Click below to download the final program for the 2016 Central Banking Series Conference in Dublin, 28 – 29 September.
Organized by Michael Drury and Jill Fornito of the Global Interdependence Center, and IABCN Founder and Chairman Emeritus, Bill McLaughlin.
Supported by IABCN members, SmartInvest.
